Geneva Partners’s Celgene Corp CELG Stock Holding History

Geneva Partners’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,108	Closed	-$4.1M	–	96
2017 Q3	$4.1M	Buy	+28,108	New	+$3.83M	3.23%	5
2016 Q2	$3.18M	Buy	+24,473	New	+$2.53M	2.85%	7

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geneva Partners's CELG Position: Q4 2017 in Review

Geneva Partners sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 28,108 shares — an estimated $4.1M sold.

Geneva Partners first reported a position in CELG in Q2 2016 and held it in 2 quarters. The position peaked at $4.1M in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

Geneva Partners reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
Geneva Partners sold 28,108 Celgene Corp shares in Q4 2017, an estimated $4.1M.
Geneva Partners first reported a position in Celgene Corp in Q2 2016 and held it in 2 quarters.
Geneva Partners's Celgene Corp position peaked at $4.1M in Q3 2017.
1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Geneva Partners's 13F filing for Q4 2017, filed 8 Feb 2018.